Skip to main content
Prescription drug costs image by TaxRebate.org.uk via Flickr

The Case for a Public Option for the Drug Industry

Dana Brown

Dana Brown

Director of the Next System Project more

Isaiah J. Poole

Isaiah J. Poole

Editorial Manager, The Next System Project more

Health & Wellbeing

Under siege from thousands of lawsuits from federal, state, and local governments for its role in the deadly opioid addiction crisis, drug manufacturer Purdue Pharma reached a tentative settlement with some of the plaintiffs in which Purdue would transform itself through the bankruptcy process from a typical, profit-chasing drugmaker into a “public beneficiary company.” The proposition raises an important question: If plaintiffs are open to the idea of turning Purdue into a public trust run by appointees of a federal bankruptcy judge—one that would distribute its profits to state and local governments—why not take one more step? Why not create the beginnings of a network of public pharmaceutical companies like those that already exist in such countries as Sweden, Brazil, and Thailand?

Continue reading in The New Republic »

Dana Brown

Dana Brown

Director of the Next System Project more

Isaiah J. Poole

Isaiah J. Poole

Editorial Manager, The Next System Project more

More related work

All health is public health

All health is public health: Busting the myths of choice and commodity

For decades, we have been sold a myth of private health. It is a myth that our health is largely a product of individual choices and personal responsibilities. It is a myth that our healthcare is a service that private corporations can provide, and for which we must pay to survive. read more
Doctor at work

Primary health care is in critical condition. Making primary care public will restore its health—and protect ours

To avoid the catastrophic effects on our health and our economy of hollowing out our primary care system, the U.S. should create a national program for universal public primary care. read more
Public pharmaceutical

Public pharmaceuticals

Public pharmaceutical enterprises are free from the constraints of profit maximization and can define their bottom line based on such values as their contributions to public health and local economic resiliency. read more